Jiangsu Kanion Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow for the year ending December 31, 2023: USD 146.63 M

Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow is USD 146.63 M for the year ending December 31, 2023, a 1.60% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD 144.32 M, a 0.96% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 142.95 M, a 33.09% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 107.41 M, a -19.20% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD 132.93 M, a 43.66% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shanghai Stock Exchange: 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd.

CEO	Mr. Yongchun Yang
IPO Date	Sept. 18, 2002
Location	China
Headquarters	No. 58 Kangyuan Road
Employees	5,443
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.

Key trends

Past 5 years